Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)

International Journal of Molecular Sciences

Volumn 15, Issue 5, 2014, Pages 7352-7379

  Takaki, Akinobu ^a   Kawai, Daisuke ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Microbiome; Non alcoholic fatty liver; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

ADIPOCYTOKINE; ADIPORON; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; CARNITINE; CETILISTAT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; HYDROGEN; LYCOPENE; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ADIPONECTIN RECEPTOR; ANTIOBESITY AGENT; ANTIOXIDANT;

CELL DEATH; CELL INFILTRATION; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; FIBROSIS; GENE; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; LIPID STORAGE; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATATIN LIKE PHOSPHOLIPASE 3 GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT PLANNING; AGONISTS; ANIMAL; COMPLICATION; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; ANTI-OBESITY AGENTS; ANTIOXIDANTS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; RECEPTORS, ADIPONECTIN;

EID: 84899764290     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15057352     Document Type: Review

References (139)

1. Pacifico, L.; Anania, C.; Martino, F.; Poggiogalle, E.; Chiarelli, F.; Arca, M.; Chiesa, C. Management of metabolic syndrome in children and adolescents. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 455-466.
2. Matteoni, C. A.; Younossi, Z. M.; Gramlich, T.; Boparai, N.; Liu, Y. C.; McCullough, A. J. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999, 116, 1413-1419.
3. Brunt, E. M.; Kleiner, D. E.; Wilson, L. A.; Unalp, A.; Behling, C. E.; Lavine, J. E.; Neuschwander-Tetri, B. A. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009, 49, 809-820.
4. Yatsuji, S.; Hashimoto, E.; Tobari, M.; Taniai, M.; Tokushige, K.; Shiratori, K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009, 24, 248-254.
5. Hatanaka, K.; Kudo, M.; Fukunaga, T.; Ueshima, K.; Chung, H.; Minami, Y.; Sakaguchi, Y.; Hagiwara, S.; Orino, A.; Osaki, Y. Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCC. Intervirology 2007, 50, 24-31.
6. Fassio, E.; Alvarez, E.; Dominguez, N.; Landeira, G.; Longo, C. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004, 40, 820-826.
7. Ono, M.; Saibara, T. Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J. Gastroenterol. 2006, 41, 725-732.
8. Gentile, C. L.; Pagliassotti, M. J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2008, 19, 567-576.
9. Yoshimoto, S.; Loo, T. M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita, H.; Hattori, M.; et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499, 97-101.
10. Pessayre, D. Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2007, 22, S20-S27.
11. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Diehl, A. M.; Brunt, E. M.; Cusi, K.; Charlton, M.; Sanyal, A. J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005-2023.
12. Steinhubl, S. R. Why have antioxidants failed in clinical trials? Am. J. Cardiol. 2008, 101, 14D-19D.
13. Hackam, D. G. Review: Antioxidant supplements for primary and secondary prevention do not decrease mortality. ACP J. Club 2007, 147, 4.
14. Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L. A.; Boerwinkle, E.; Cohen, J. C.; Hobbs, H. H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40, 1461-1465.
15. Qiao, A.; Liang, J.; Ke, Y.; Li, C.; Cui, Y.; Shen, L.; Zhang, H.; Cui, A.; Liu, X.; Liu, C.; et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011, 54, 509-521.
16. Li, J. Z.; Huang, Y.; Karaman, R.; Ivanova, P. T.; Brown, H. A.; Roddy, T.; Castro-Perez, J.; Cohen, J. C.; Hobbs, H. H. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Investig. 2012, 122, 4130-4144.
17. Valenti, L.; Alisi, A.; Galmozzi, E.; Bartuli, A.; del Menico, B.; Alterio, A.; Dongiovanni, P.; Fargion, S.; Nobili, V. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52, 1274-1280.
18. Kawaguchi, T.; Sumida, Y.; Umemura, A.; Matsuo, K.; Takahashi, M.; Takamura, T.; Yasui, K.; Saibara, T.; Hashimoto, E.; Kawanaka, M.; et al. Japan Study Group of Nonalcoholic Fatty Liver, D. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012, 7, e38322.
19. Hassan, M. M.; Kaseb, A.; Etzel, C. J.; El-Serag, H.; Spitz, M. R.; Chang, P.; Hale, K. S.; Liu, M.; Rashid, A.; Shama, M.; et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol. Carcinog. 2013, 52, E139-E147.
20. Singal, A. G.; Manjunath, H.; Yopp, A. C.; Beg, M. S.; Marrero, J. A.; Gopal, P.; Waljee, A. K. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis. Am. J. Gastroenterol. 2014, 109, 325-334.
21. Takeuchi, Y.; Ikeda, F.; Moritou, Y.; Hagihara, H.; Yasunaka, T.; Kuwaki, K.; Miyake, Y.; Ohnishi, H.; Nakamura, S.; Shiraha, H.; et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J. Gastroenterol. 2013, 48, 405-412.
22. Nakamura, M.; Kanda, T.; Nakamoto, S.; Miyamura, T.; Jiang, X.; Wu, S.; Yokosuka, O. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One 2013, 8, e81312.
23. Lallukka, S.; Sevastianova, K.; Perttila, J.; Hakkarainen, A.; Orho-Melander, M.; Lundbom, N.; Olkkonen, V. M.; Yki-Jarvinen, H. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013, 56, 886-892.
24. Sookoian, S.; Pirola, C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53, 1883-1894.
25. Csak, T.; Ganz, M.; Pespisa, J.; Kodys, K.; Dolganiuc, A.; Szabo, G. Fatty acids and endotoxin activate inflammasome in hepatocytes which release danger signals to activate immune cells in steatohepatitis. Hepatology 2011, 54, 133-144.
26. Brun, P.; Castagliuolo, I.; di Leo, V.; Buda, A.; Pinzani, M.; Palu, G.; Martines, D. Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G518-G525.
27. Cani, P. D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A. M.; Delzenne, N. M.; Burcelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57, 1470-1481.
28. Miele, L.; Valenza, V.; La Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Masciana, R.; Forgione, A.; Gabrieli, M. L.; Perotti, G.; et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49, 1877-1887.
29. Cani, P. D.; Amar, J.; Iglesias, M. A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A. M.; Fava, F.; Tuohy, K. M.; Chabo, C.; et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761-1772.
30. Cani, P. D.; Possemiers, S.; van de Wiele, T.; Guiot, Y.; Everard, A.; Rottier, O.; Geurts, L.; Naslain, D.; Neyrinck, A.; Lambert, D. M.; et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58, 1091-1103.
31. Dominguez-Bello, M. G.; Blaser, M. J.; Ley, R. E.; Knight, R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011, 140, 1713-1719.
32. Mouzaki, M.; Comelli, E. M.; Arendt, B. M.; Bonengel, J.; Fung, S. K.; Fischer, S. E.; McGilvray, I. D.; Allard, J. P. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58, 120-127.
33. Schnabl, B.; Brenner, D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014, doi: 10. 1053/j. gastro. 2014. 01. 020.
34. Henao-Mejia, J.; Elinav, E.; Jin, C.; Hao, L.; Mehal, W. Z.; Strowig, T.; Thaiss, C. A.; Kau, A. L.; Eisenbarth, S. C.; Jurczak, M. J.; et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482, 179-185.
35. Tamaki, N.; Takaki, A.; Tomofuji, T.; Endo, Y.; Kasuyama, K.; Ekuni, D.; Yasunaka, T.; Yamamoto, K.; Morita, M. Stage of hepatocellular carcinoma is associated with periodontitis. J. Clin. Periodontol. 2011, 38, 1015-1020.
36. Yoneda, M.; Naka, S.; Nakano, K.; Wada, K.; Endo, H.; Mawatari, H.; Imajo, K.; Nomura, R.; Hokamura, K.; Ono, M.; et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012, 12, 16.
37. Xu, R. Y.; Wan, Y. P.; Fang, Q. Y.; Lu, W.; Cai, W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J. Clin. Biochem. Nutr. 2012, 50, 72-77.
38. Macfarlane, S. Antibiotic treatments and microbes in the gut. Environ. Microbiol. 2014, 16, 919-924.
39. Bhala, N.; Jouness, R. I.; Bugianesi, E. Epidemiology and natural history of patients with NAFLD. Curr. Pharm. Des. 2013, 19, 5169-5176.
40. Eguchi, Y.; Eguchi, T.; Mizuta, T.; Ide, Y.; Yasutake, T.; Iwakiri, R.; Hisatomi, A.; Ozaki, I.; Yamamoto, K.; Kitajima, Y.; et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J. Gastroenterol. 2006, 41, 462-469.
41. Nobili, V.; Svegliati-Baroni, G.; Alisi, A.; Miele, L.; Valenti, L.; Vajro, P. A 360-degree overview of paediatric NAFLD: Recent insights. J. Hepatol. 2013, 58, 1218-1229.
42. Hong, H. C.; Hwang, S. Y.; Choi, H. Y.; Yoo, H. J.; Seo, J. A.; Kim, S. G.; Kim, N. H.; Baik, S. H.; Choi, D. S.; Choi, K. M. The relationship between sarcopenia and non-alcoholic fatty liver disease: The Korean sarcopenic obesity study. Hepatology 2013, doi: 10. 1002/hep. 26716.
43. + T-cell populations and insulin resistance in obese individuals. Gastroenterology 2013, 145, 366-374.
44. Harley, I. T.; Stankiewicz, T. E.; Giles, D. A.; Softic, S.; Flick, L. M.; Cappelletti, M.; Sheridan, R.; Xanthakos, S. A.; Steinbrecher, K. A.; Sartor, R. B.; et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 2013, doi: 10. 1002/hep. 26746.
45. Musso, G.; Cassader, M.; de Michieli, F.; Rosina, F.; Orlandi, F.; Gambino, R. Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012, 56, 933-942.
46. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87, 1409-1439.
47. Bernsmeier, C.; Meyer-Gerspach, A. C.; Blaser, L. S.; Jeker, L.; Steinert, R. E.; Heim, M. H.; Beglinger, C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic Fatty liver disease. PLoS One 2014, 9, e87488.
48. Corbetta, S.; Bulfamante, G.; Cortelazzi, D.; Barresi, V.; Cetin, I.; Mantovani, G.; Bondioni, S.; Beck-Peccoz, P.; Spada, A. Adiponectin expression in human fetal tissues during mid-and late gestation. J. Clin. Endocrinol. Metab. 2005, 90, 2397-2402.
49. Polyzos, S. A.; Toulis, K. A.; Goulis, D. G.; Zavos, C.; Kountouras, J. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2011, 60, 313-326.
50. Carbone, F.; La Rocca, C.; Matarese, G. Immunological functions of leptin and adiponectin. Biochimie 2012, 94, 2082-2088.
51. Handa, P.; Maliken, B. D.; Nelson, J. E.; Morgan-Stevenson, V.; Messner, D. J.; Dhillon, B. K.; Klintworth, H. M.; Beauchamp, M.; Yeh, M. M.; Elfers, C. T.; et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 2013, doi: 10. 1002/hep. 26946.
52. Kaser, S.; Moschen, A.; Cayon, A.; Kaser, A.; Crespo, J.; Pons-Romero, F.; Ebenbichler, C. F.; Patsch, J. R.; Tilg, H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54, 117-121.
53. Nannipieri, M.; Cecchetti, F.; Anselmino, M.; Mancini, E.; Marchetti, G.; Bonotti, A.; Baldi, S.; Solito, B.; Giannetti, M.; Pinchera, A.; et al. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes. Surg. 2009, 19, 467-474.
54. Ma, H.; Gomez, V.; Lu, L.; Yang, X.; Wu, X.; Xiao, S. Y. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009, 24, 233-237.
55. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X. X.; Pandey, S. K.; Bhanot, S.; Monia, B. P.; Li, Y. X.; Diehl, A. M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45, 1366-1374.
56. Yu, X. X.; Murray, S. F.; Pandey, S. K.; Booten, S. L.; Bao, D.; Song, X. Z.; Kelly, S.; Chen, S.; McKay, R.; Monia, B. P.; et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 2005, 42, 362-371.
57. Kantartzis, K.; Machicao, F.; Machann, J.; Schick, F.; Fritsche, A.; Haring, H. U.; Stefan, N. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin. Sci. (Lond.) 2009, 116, 531-537.
58. McPherson, S.; Stewart, S. F.; Henderson, E.; Burt, A. D.; Day, C. P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59, 1265-1269.
59. Ratziu, V.; Massard, J.; Charlotte, F.; Messous, D.; Imbert-Bismut, F.; Bonyhay, L.; Tahiri, M.; Munteanu, M.; Thabut, D.; Cadranel, J. F.; et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006, 6, 6.
60. Machado, M. V.; Cortez-Pinto, H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J. Hepatol. 2013, 58, 1007-1019.
61. Feldstein, A. E.; Alkhouri, N.; de Vito, R.; Alisi, A.; Lopez, R.; Nobili, V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am. J. Gastroenterol. 2013, 108, 1526-1531.
62. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011, 43, 617-649.
63. Cusi, K.; Chang, Z.; Harrison, S.; Lomonaco, R.; Bril, F.; Orsak, B.; Ortiz-Lopez, C.; Hecht, J.; Feldstein, A. E.; Webb, A.; et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J. Hepatol. 2014, 60, 167-174.
64. Kucukoglu, O.; Guldiken, N.; Chen, Y.; Usachov, V.; El-Heliebi, A.; Haybaeck, J.; Denk, H.; Trautwein, C.; Strnad, P. High-fat diet triggers Mallory-Denk body formation via misfolding and crosslinking of excess keratin 8. Hepatology 2014, doi: 10. 1002/hep. 27068.
65. Musso, G.; Gambino, R.; Cassader, M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 2013, 52, 175-191.
66. Fu, S.; Yang, L.; Li, P.; Hofmann, O.; Dicker, L.; Hide, W.; Lin, X.; Watkins, S. M.; Ivanov, A. R.; Hotamisligil, G. S. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 2011, 473, 528-531.
67. Park, S. W.; Zhou, Y.; Lee, J.; Lu, A.; Sun, C.; Chung, J.; Ueki, K.; Ozcan, U. The regulatory subunits of PI3K, p85alpha and p85beta, interact with XBP-1 and increase its nuclear translocation. Nat. Med. 2010, 16, 429-437.
68. So, J. S.; Hur, K. Y.; Tarrio, M.; Ruda, V.; Frank-Kamenetsky, M.; Fitzgerald, K.; Koteliansky, V.; Lichtman, A. H.; Iwawaki, T.; Glimcher, L. H.; et al. Silencing of lipid metabolism genes through IRE1alpha-mediated mRNA decay lowers plasma lipids in mice. Cell Metab. 2012, 16, 487-499.
69. 2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity. Proc. Natl. Acad. Sci. USA 2010, 107, 19320-19325.
70. 2+-ATPases, modulates nitric oxide production and cell death of primary rat hepatocytes in culture. Cell Biol. Toxicol. 2007, 23, 337-354.
71. Lake, A. D.; Novak, P.; Hardwick, R. N.; Flores-Keown, B.; Zhao, F.; Klimecki, W. T.; Cherrington, N. J. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicol. Sci. 2014, 137, 26-35.
72. Barker, J. R.; Koestler, B. J.; Carpenter, V. K.; Burdette, D. L.; Waters, C. M.; Vance, R. E.; Valdivia, R. H. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. mBio 2013, 4, e00018: 1-e00018: 13.
73. De Minicis, S.; Candelaresi, C.; Agostinelli, L.; Taffetani, S.; Saccomanno, S.; Rychlicki, C.; Trozzi, L.; Marzioni, M.; Benedetti, A.; Svegliati-Baroni, G. Endoplasmic Reticulum stress induces hepatic stellate cell apoptosis and contributes to fibrosis resolution. Liver Int. 2012, 32, 1574-1584.
74. Kawai, D.; Takaki, A.; Nakatsuka, A.; Wada, J.; Tamaki, N.; Yasunaka, T.; Koike, K.; Tsuzaki, R.; Matsumoto, K.; Miyake, Y.; et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology 2012, 56, 912-921.
75. Bugianesi, E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 2007, 11, 191-207.
76. Mittler, R.; Vanderauwera, S.; Suzuki, N.; Miller, G.; Tognetti, V. B.; Vandepoele, K.; Gollery, M.; Shulaev, V.; van Breusegem, F. ROS signaling: The new wave? Trends Plant Sci. 2011, 16, 300-309.
77. Cortez-Pinto, H.; Chatham, J.; Chacko, V. P.; Arnold, C.; Rashid, A.; Diehl, A. M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study. JAMA 1999, 282, 1659-1664.
78. Serviddio, G.; Bellanti, F.; Tamborra, R.; Rollo, T.; Romano, A. D.; Giudetti, A. M.; Capitanio, N.; Petrella, A.; Vendemiale, G.; Altomare, E. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur. J. Clin. Investig. 2008, 38, 245-252.
79. Brand, M. D. The sites and topology of mitochondrial superoxide production. Exp. Gerontol. 2010, 45, 466-472.
80. Nelson, J. E.; Wilson, L.; Brunt, E. M.; Yeh, M. M.; Kleiner, D. E.; Unalp-Arida, A.; Kowdley, K. V. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011, 53, 448-457.
81. Siddique, A.; Nelson, J. E.; Aouizerat, B.; Yeh, M. M.; Kowdley, K. V.; Network, N. C. R. Iron deficiency in patients with nonalcoholic fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin. Gastroenterol. Hepatol. 2013, doi: 10. 1016/j. cgh. 2013. 11. 017.
82. Scarpulla, R. C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta 2011, 1813, 1269-1278.
83. Aharoni-Simon, M.; Hann-Obercyger, M.; Pen, S.; Madar, Z.; Tirosh, O. Fatty liver is associated with impaired activity of PPARgamma-coactivator 1alpha (PGC1alpha) and mitochondrial biogenesis in mice. Lab. Investig. 2011, 91, 1018-1028.
84. Wang, B.; Hsu, S. H.; Frankel, W.; Ghoshal, K.; Jacob, S. T. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012, 56, 186-197.
85. Chiappini, F.; Barrier, A.; Saffroy, R.; Domart, M. C.; Dagues, N.; Azoulay, D.; Sebagh, M.; Franc, B.; Chevalier, S.; Debuire, B.; et al. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab. Investig. 2006, 86, 154-165.
86. Rolo, A. P.; Teodoro, J. S.; Palmeira, C. M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52, 59-69.
87. Hui, J. M.; Hodge, A.; Farrell, G. C.; Kench, J. G.; Kriketos, A.; George, J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004, 40, 46-54.
88. Hernandez-Gea, V.; Hilscher, M.; Rozenfeld, R.; Lim, M. P.; Nieto, N.; Werner, S.; Devi, L. A.; Friedman, S. L. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J. Hepatol. 2013, 59, 98-104.
89. Blaner, W. S.; O'Byrne, S. M.; Wongsiriroj, N.; Kluwe, J.; D'Ambrosio, D. M.; Jiang, H.; Schwabe, R. F.; Hillman, E. M.; Piantedosi, R.; Libien, J. Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage. Biochim. Biophys. Acta 2009, 1791, 467-473.
90. Hernandez-Gea, V.; Ghiassi-Nejad, Z.; Rozenfeld, R.; Gordon, R.; Fiel, M. I.; Yue, Z.; Czaja, M. J.; Friedman, S. L. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012, 142, 938-946.
91. Lanthier, N.; Molendi-Coste, O.; Horsmans, Y.; van Rooijen, N.; Cani, P. D.; Leclercq, I. A. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G107-G116.
92. Gadd, V. L.; Skoien, R.; Powell, E. E.; Fagan, K. J.; Winterford, C.; Horsfall, L.; Irvine, K.; Clouston, A. D. The portal inflammatory infiltrate and ductular reaction in human non-alcoholic fatty liver disease. Hepatology 2013, 59, 1393-1405.
93. Glass, C. K.; Saijo, K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10, 365-376.
94. Li, P.; Spann, N. J.; Kaikkonen, M. U.; Lu, M.; Oh da, Y.; Fox, J. N.; Bandyopadhyay, G.; Talukdar, S.; Xu, J.; Lagakos, W. S.; et al. NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell 2013, 155, 200-214.
95. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15, 914-920.
96. Talukdar, S.; Oh da, Y.; Bandyopadhyay, G.; Li, D.; Xu, J.; McNelis, J.; Lu, M.; Li, P.; Yan, Q.; Zhu, Y.; et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 2012, 18, 1407-1412.
97. Wagnerberger, S.; Spruss, A.; Kanuri, G.; Volynets, V.; Stahl, C.; Bischoff, S. C.; Bergheim, I. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br. J. Nutr. 2012, 107, 1727-1738.
98. Miura, K.; Yang, L.; van Rooijen, N.; Brenner, D. A.; Ohnishi, H.; Seki, E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 2013, 57, 577-589.
99. Rivera, C. A.; Gaskin, L.; Allman, M.; Pang, J.; Brady, K.; Adegboyega, P.; Pruitt, K. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol. 2010, 10, 52.
100. Tomita, K.; Teratani, T.; Suzuki, T.; Shimizu, M.; Sato, H.; Narimatsu, K.; Okada, Y.; Kurihara, C.; Irie, R.; Yokoyama, H.; et al. Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014, 59, 154-169.
101. Leroux, A.; Ferrere, G.; Godie, V.; Cailleux, F.; Renoud, M. L.; Gaudin, F.; Naveau, S.; Prevot, S.; Makhzami, S.; Perlemuter, G.; et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J. Hepatol. 2012, 57, 141-149.
102. Vijay-Kumar, M.; Sanders, C. J.; Taylor, R. T.; Kumar, A.; Aitken, J. D.; Sitaraman, S. V.; Neish, A. S.; Uematsu, S.; Akira, S.; Williams, I. R.; et al. Deletion of TLR5 results in spontaneous colitis in mice. J. Clin. Investig. 2007, 117, 3909-3921.
103. Vijay-Kumar, M.; Aitken, J. D.; Carvalho, F. A.; Cullender, T. C.; Mwangi, S.; Srinivasan, S.; Sitaraman, S. V.; Knight, R.; Ley, R. E.; Gewirtz, A. T. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328, 228-231.
104. Letran, S. E.; Lee, S. J.; Atif, S. M.; Flores-Langarica, A.; Uematsu, S.; Akira, S.; Cunningham, A. F.; McSorley, S. J. TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen. J. Immunol. 2011, 186, 5406-5412.
105. Goodpaster, B. H.; Delany, J. P.; Otto, A. D.; Kuller, L.; Vockley, J.; South-Paul, J. E.; Thomas, S. B.; Brown, J.; McTigue, K.; Hames, K. C.; et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: A randomized trial. JAMA 2010, 304, 1795-1802.
106. Neuschwander-Tetri, B. A.; Ford, D. A.; Acharya, S.; Gilkey, G.; Basaranoglu, M.; Tetri, L. H.; Brunt, E. M. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012, 47, 941-950.
107. Soetens, B.; Braet, C.; Moens, E. Thought suppression in obese and non-obese restrained eaters: Piece of cake or forbidden fruit? Eur. Eat. Disord. Rev. 2008, 16, 67-76.
108. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Diehl, A. M.; Brunt, E. M.; Cusi, K.; Charlton, M.; Sanyal, A. J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142, 1592-1609.
109. Sanyal, A. J.; Chalasani, N.; Kowdley, K. V.; McCullough, A.; Diehl, A. M.; Bass, N. M.; Neuschwander-Tetri, B. A.; Lavine, J. E.; Tonascia, J.; Unalp, A.; et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362, 1675-1685.
110. Hoofnagle, J. H.; van Natta, M. L.; Kleiner, D. E.; Clark, J. M.; Kowdley, K. V.; Loomba, R.; Neuschwander-Tetri, B. A.; Sanyal, A. J.; Tonascia, J. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2013, 38, 134-143.
111. Bast, A.; Haenen, G. R. Ten misconceptions about antioxidants. Trends Pharmacol. Sci. 2013, 34, 430-436.
112. Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013, 3, 120144.
113. Yae, T.; Tsuchihashi, K.; Ishimoto, T.; Motohara, T.; Yoshikawa, M.; Yoshida, G. J.; Wada, T.; Masuko, T.; Mogushi, K.; Tanaka, H.; et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun. 2012, 3, 883.
114. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug Discov. 2009, 8, 579-591.
115. Ohta, S. Recent progress toward hydrogen medicine: Potential of molecular hydrogen for preventive and therapeutic applications. Curr. Pharm. Des. 2011, 17, 2241-2252.
116. Musso, G.; Cassader, M.; Rosina, F.; Gambino, R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55, 885-904.
117. Svegliati-Baroni, G.; Saccomanno, S.; Rychlicki, C.; Agostinelli, L.; de Minicis, S.; Candelaresi, C.; Faraci, G.; Pacetti, D.; Vivarelli, M.; Nicolini, D.; et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011, 31, 1285-1297.
118. Cuthbertson, D. J.; Irwin, A.; Gardner, C. J.; Daousi, C.; Purewal, T.; Furlong, N.; Goenka, N.; Thomas, E. L.; Adams, V. L.; Pushpakom, S. P.; et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012, 7, e50117.
119. Kern, M.; Kloting, N.; Niessen, H. G.; Thomas, L.; Stiller, D.; Mark, M.; Klein, T.; Bluher, M. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012, 7, e38744.
120. Zein, C. O.; Lopez, R.; Fu, X.; Kirwan, J. P.; Yerian, L. M.; McCullough, A. J.; Hazen, S. L.; Feldstein, A. E. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. Hepatology 2012, 56, 1291-1299.
121. Zein, C. O.; Yerian, L. M.; Gogate, P.; Lopez, R.; Kirwan, J. P.; Feldstein, A. E.; McCullough, A. J. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 2011, 54, 1610-1619.
122. Nelson, A.; Torres, D. M.; Morgan, A. E.; Fincke, C.; Harrison, S. A. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J. Clin. Gastroenterol. 2009, 43, 990-994.
123. Deushi, M.; Nomura, M.; Kawakami, A.; Haraguchi, M.; Ito, M.; Okazaki, M.; Ishii, H.; Yoshida, M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007, 581, 5664-5670.
124. Yoneda, M.; Fujita, K.; Nozaki, Y.; Endo, H.; Takahashi, H.; Hosono, K.; Suzuki, K.; Mawatari, H.; Kirikoshi, H.; Inamori, M.; et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol. Res. 2010, 40, 613-621.
125. Ushio, M.; Nishio, Y.; Sekine, O.; Nagai, Y.; Maeno, Y.; Ugi, S.; Yoshizaki, T.; Morino, K.; Kume, S.; Kashiwagi, A.; et al. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. Am. J. Physiol. Endocrinol. Metab. 2013, 305, E293-E304.
126. Leuschner, U. F.; Lindenthal, B.; Herrmann, G.; Arnold, J. C.; Rossle, M.; Cordes, H. J.; Zeuzem, S.; Hein, J.; Berg, T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52, 472-479.
127. Pietu, F.; Guillaud, O.; Walter, T.; Vallin, M.; Hervieu, V.; Scoazec, J. Y.; Dumortier, J. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin. Res. Hepatol. Gastroenterol. 2012, 36, 146-155.
128. Ford, A. C.; Peyrin-Biroulet, L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: Meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 2013, 108, 1268-1276.
129. Endo, H.; Niioka, M.; Kobayashi, N.; Tanaka, M.; Watanabe, T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: New insight into the probiotics for the gut-liver axis. PLoS One 2013, 8, e63388.
130. Carter, R.; Mouralidarane, A.; Ray, S.; Soeda, J.; Oben, J. Recent advancements in drug treatment of obesity. Clin. Med. 2012, 12, 456-460.
131. Malaguarnera, M.; Gargante, M. P.; Russo, C.; Antic, T.; Vacante, M.; Avitabile, T.; Li Volti, G.; Galvano, F. L-carnitine supplementation to diet: A new tool in treatment of nonalcoholic steatohepatitis-A randomized and controlled clinical trial. Am. J. Gastroenterol. 2010, 105, 1338-1345.
132. Xia, Y.; Li, Q.; Zhong, W.; Dong, J.; Wang, Z.; Wang, C. L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol. Metab. Syndr. 2011, 3, 31.
133. Ip, B. C.; Wang, X. D. Non-alcoholic steatohepatitis and hepatocellular carcinoma: Implications for lycopene intervention. Nutrients 2014, 6, 124-162.
134. Ip, B. C.; Hu, K. Q.; Liu, C.; Smith, D. E.; Obin, M. S.; Ausman, L. M.; Wang, X. D. Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice. Cancer Prev. Res. 2013, 6, 1304-1316.
135. Kim, Y. I.; Hirai, S.; Goto, T.; Ohyane, C.; Takahashi, H.; Tsugane, T.; Konishi, C.; Fujii, T.; Inai, S.; Iijima, Y.; et al. Potent PPARalpha activator derived from tomato juice, 13-oxo-9, 11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice. PLoS One 2012, 7, e31317.
136. Ohsawa, I.; Ishikawa, M.; Takahashi, K.; Watanabe, M.; Nishimaki, K.; Yamagata, K.; Katsura, K.; Katayama, Y.; Asoh, S.; Ohta, S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 2007, 13, 688-694.
137. Sun, H.; Chen, L.; Zhou, W.; Hu, L.; Li, L.; Tu, Q.; Chang, Y.; Liu, Q.; Sun, X.; Wu, M.; et al. The protective role of hydrogen-rich saline in experimental liver injury in mice. J. Hepatol. 2011, 54, 471-480.
138. Ozcan, U.; Yilmaz, E.; Ozcan, L.; Furuhashi, M.; Vaillancourt, E.; Smith, R. O.; Gorgun, C. Z.; Hotamisligil, G. S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313, 1137-1140.
139. Okada-Iwabu, M.; Yamauchi, T.; Iwabu, M.; Honma, T.; Hamagami, K.; Matsuda, K.; Yamaguchi, M.; Tanabe, H.; Kimura-Someya, T.; Shirouzu, M.; et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503, 493-499.